{
  "id": 1515563,
  "title": "Argenx jumps on Phase 3 data for blockbuster Vyvgart",
  "url": "https://urgent.news/2026/08/17/argenx-jumps-on-phase-3-data-for-blockbuster-vyvgart",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-17T16:12:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/argenx-phase-3-data-vyvgart-IMNM-DM/828025/"
  },
  "original_language": "en",
  "account": null,
  "summary": "The latest results give investors confidence in the drug's ability to be approved in another indication for which there are no approved treatments.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis",
        "url": "https://urgent.news/2026/08/17/argenx-declares-phase-3-win-for-vyvgart-hytrulo-in-autoimmune-myositis",
        "published": "2026-08-17T10:51:24.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}